2020201920182017201620152014 March 11, 2020 Summary ToggleSpero Therapeutics Receives FDA Orphan Drug Designation for SPR720 for the Treatment of Nontuberculous Mycobacterial (NTM) Infection March 05, 2020 Summary ToggleSpero Therapeutics Announces Closing of Rights Offering February 28, 2020 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 26, 2020 Summary ToggleSpero Therapeutics to Present at March Investor Conferences February 11, 2020 Summary ToggleSpero Therapeutics Announces Commencement of Rights Offering February 05, 2020 Summary ToggleSpero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development January 31, 2020 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 30, 2020 Summary ToggleSpero Therapeutics Announces Proposed Rights Offering January 13, 2020 Summary ToggleSpero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense December 04, 2019 Summary ToggleSpero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
